CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic ...
Phase 3
Cleveland, Ohio, United States and 37 other locations
or venetoclax plus rituximab retreatment) in participants with chronic lymphocytic leukemia (CLL) or small lymphocytic...
Phase 3
Cleveland, Ohio, United States and 105 other locations
objective of this study is to compare the efficacy of sonrotoclax plus zanubrutinib versus venetoclax plus obinutuzumab in participants with chronic...
Phase 3
Cleveland, Ohio, United States and 210 other locations
This is a Phase 1/2, open-label, multicenter study to determine the efficacy and safety of JCAR017 in adult subjects with relapsed or refractory CLL...
Phase 1, Phase 2
Cleveland, Ohio, United States and 82 other locations
Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study...
Phase 3
Cleveland, Ohio, United States and 67 other locations
The purpose of this study is to compare the efficacy and safety of fixed duration pirtobruitinib (LOXO-305) with VR (Arm A) compared to VR alone (Arm...
Phase 3
Cleveland, Ohio, United States and 179 other locations
This is an open-label, multi-center Phase 1/2 study of oral LOXO-305 (pirtobrutinib) in patients with CLL/SLL and NHL who have failed or are intolera...
Phase 1, Phase 2
Cleveland, Ohio, United States and 55 other locations
in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lympho...
Phase 1
Cleveland, Ohio, United States and 5 other locations
This is a first-in-human Phase 1a/1b multicenter, open-label study designed to evaluate the safety and anti-cancer activity of NX-5948 in patients wi...
Phase 1
Cleveland, Ohio, United States and 60 other locations
Assess the safety and tolerability, identify dose-limiting toxicities (DLT) and determine the maximum tolerated dose (MTD) / recommended phase 2 dose...
Phase 1
Cleveland, Ohio, United States and 8 other locations
Clinical trials
Research sites
Resources
Legal